In our experience using the KPC model, the addition of agonistic CD40 antibody, aimed at licensing dendritic cells to activate anti-tumor T cells, has been the single most potent method to sensitize tumor-bearing mice to PD-1, CTLA-4, or combination immune checkpoint blockade – as has been recently reviewed (18). Here, CD40 is linked to neoplasm.